Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Oral GLP-1 Approaches Commercial Inflection by 2028 GLP-1 Weight Loss Drug Market Revenue Share, CAGR, and Primary Drivers by Route 2026 Subcutaneous injectable administration commands 81.7% GLP-1 market revenue share in 2026 as the weekly autoinjector format delivers clinical efficacy, dose consistency, and patient convenience superior to daily injectable alternatives
Retail pharmaceutical pricing (Wegovy/Mounjaro as proxies for future retatrutide pricing) runs $1,000-1,400 monthly without insurance, or $12,000-16,800 annually
GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome
Petersen N, Reimann F, Bartfeld S, Farin HF, Ringnalda FC, Vries RGJ, et al
Who should not take semaglutide
3.2 Clinical application of GLP-1RAs GLP-1RA has been widely acknowledged at home and abroad for its hypoglycemic effects, safe use and beneficial effect on human metabolism
